JP2010512324A - ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法 - Google Patents

ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法 Download PDF

Info

Publication number
JP2010512324A
JP2010512324A JP2009540318A JP2009540318A JP2010512324A JP 2010512324 A JP2010512324 A JP 2010512324A JP 2009540318 A JP2009540318 A JP 2009540318A JP 2009540318 A JP2009540318 A JP 2009540318A JP 2010512324 A JP2010512324 A JP 2010512324A
Authority
JP
Japan
Prior art keywords
antibody
upar
binding
antigen
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009540318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512324A5 (enExample
Inventor
パッリー グラハム
ピー．マザル アンドレウ
Original Assignee
アッテヌオン エル エル シー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッテヌオン エル エル シー filed Critical アッテヌオン エル エル シー
Publication of JP2010512324A publication Critical patent/JP2010512324A/ja
Publication of JP2010512324A5 publication Critical patent/JP2010512324A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2009540318A 2006-12-08 2007-12-07 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法 Pending JP2010512324A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87362706P 2006-12-08 2006-12-08
US93003407P 2007-05-11 2007-05-11
PCT/US2007/025105 WO2008073312A2 (en) 2006-12-08 2007-12-07 Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014154804A Division JP6019457B2 (ja) 2006-12-08 2014-07-30 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2010512324A true JP2010512324A (ja) 2010-04-22
JP2010512324A5 JP2010512324A5 (enExample) 2011-02-03

Family

ID=39512272

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009540318A Pending JP2010512324A (ja) 2006-12-08 2007-12-07 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法
JP2014154804A Active JP6019457B2 (ja) 2006-12-08 2014-07-30 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014154804A Active JP6019457B2 (ja) 2006-12-08 2014-07-30 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法

Country Status (9)

Country Link
US (1) US8105602B2 (enExample)
EP (1) EP2117571B1 (enExample)
JP (2) JP2010512324A (enExample)
CA (1) CA2671971C (enExample)
DK (1) DK2117571T3 (enExample)
ES (1) ES2636451T3 (enExample)
PL (1) PL2117571T3 (enExample)
PT (1) PT2117571T (enExample)
WO (1) WO2008073312A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530510A (ja) * 2013-08-01 2016-09-29 ザ ジェネラル ホスピタル コーポレイション 非グリコシル化ｓｕＰＡＲバイオマーカー及びその使用
JP2023532426A (ja) * 2020-06-15 2023-07-28 モノパー セラピューティクス、インコーポレイテッド 重症ＣＯＶＩＤ－１９疾患の治療のためのウロキナーゼプラスミノーゲン活性化因子受容体（ｕＰＡＲ）の正確な放射線免疫治療標的化

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070047246A (ko) * 2004-05-25 2007-05-04 아테뉴온, 엘엘씨 유로키나아제형 플라스미노겐 활성인자(ｕＰＡ)와 그의수용체(ｕＰＡＲ)의 복합체에 결합하여 하류 ｕＰＡＲ상호작용을 억제하는 리간드의 동정 및 진단 또는치료에서의 용도
US8105602B2 (en) 2006-12-08 2012-01-31 Tactic Pharma, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
US8697081B2 (en) * 2008-04-09 2014-04-15 The Regents Of The University Of Michigan Method of modulating neovascularization
WO2011028531A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
PT2510012T (pt) * 2009-12-09 2017-07-13 Bayer Pharma AG Anticorpos anti-c4.4a e utilizações dos mesmos
EP2534179A4 (en) * 2010-02-12 2013-07-17 Univ California UPAR BINDING AGENT AND METHOD FOR THEIR USE
BR112013016107A2 (pt) 2010-12-22 2017-04-04 Ifom Fond Inst Firc Di Oncologia Molecolare molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
CN103930128A (zh) 2011-08-05 2014-07-16 意大利癌症研究基金会分子肿瘤学研究所(Ifom) 组成型活性uPAR变体及其在抑制性抗体的生成与分离中的应用
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
WO2015004148A1 (en) 2013-07-08 2015-01-15 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG10202112047TA (en) 2015-09-18 2021-12-30 Baylor College Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7140362B2 (ja) * 2018-04-09 2022-09-21 国立大学法人東海国立大学機構 活性型組換えアクロシン
EP4341265A4 (en) * 2021-05-21 2025-07-23 Northstar Medical Tech Llc TRIVALENT RADIOISTOPE BIO-TARGETED RADIOPHARMACEUTICAL, METHODS OF PREPARATION AND USE
CN116410312A (zh) * 2021-12-29 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型upar单域抗体的开发
EP4490511A2 (en) * 2022-03-07 2025-01-15 Rush University Medical Center Novel treatment of diabetes and kidney disease by inhibition of d2d3 a proteolytic upar protein
CN117264061B (zh) * 2023-11-22 2024-03-01 中山大学附属第八医院（深圳福田） 一种识别uPAR的纳米抗体及其应用
WO2025207781A1 (en) 2024-03-26 2025-10-02 Monopar Therapeutics Inc. Antibody radioisotope constructs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002062295A (ja) * 1989-04-07 2002-02-28 Cancerforskningsfonden Af 1989 (Fonden Til Fremme Af Eksperimentel Cancerforskning) ウロキナーゼ型プラスミノーゲン活性化因子レセプター
WO2005116077A2 (en) * 2004-05-25 2005-12-08 Attenuon, Llc LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY
WO2006090389A2 (en) * 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8721023D0 (en) 1987-09-07 1987-10-14 Lepetit Spa Modified plasminogen activators
IT1228881B (it) 1988-08-12 1991-07-09 Lepetit Spa Anticorpo monoclonale specifico per l'epitopo dell'urochinasi prourichinasi corrispondente alla regione denominata gfd
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
US5891664A (en) * 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
CA2094276C (en) 1990-10-18 2005-08-23 Keld Dano Antibodies against the urokinase receptor and their use
US5561220A (en) * 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
JPH07501524A (ja) 1991-11-18 1995-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ｕＰＡ−Ｒの検出・分離方法及びｕＰＡのｕＰＡ−Ｒへの結合阻止方法
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
ES2143504T3 (es) 1992-05-28 2000-05-16 Univ Toledo Uso de un material citotoxico acoplado a un material inhibidor del activador plasminogeno para la produccion de un medicamento para el tratamiento de celulas cancerigenas.
US5608110A (en) * 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
WO1995004281A1 (en) * 1993-07-27 1995-02-09 THE UNITED STATES GOVERNMENT, represented by THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION Quantitative method of measuring cancer cell urokinase and metastatic potential
US5532132A (en) * 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
JP2852192B2 (ja) * 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
US5618513A (en) * 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
KR100497017B1 (ko) 1996-03-22 2005-11-29 휴먼 게놈 사이언시즈, 인코포레이티드 고사유도분자ii
EP1042343B1 (en) 1997-11-03 2008-01-23 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
US6077508A (en) 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
DE50015293D1 (de) 1999-04-13 2008-09-11 Wilex Ag Diagnostischer und therapeutischer Einsatz von Antikörpern gegen den Urokinase-Rezeptor
DE60219888T2 (de) 2001-01-25 2008-01-17 Fondazione Centro San Raffaele Del Monte Tabor Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
US6846484B2 (en) 2001-12-28 2005-01-25 Regents Of The University Of Minnesota DTAT fusion toxin
ATE524739T1 (de) 2002-02-13 2011-09-15 American Diagnostica Inc Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten
WO2003079974A2 (en) * 2002-03-18 2003-10-02 The Arizona Board Of Regents On Behalf Of The University Of Arizona Integrin ligand
KR100470535B1 (ko) 2002-06-27 2005-02-22 재단법인서울대학교산학협력재단 유피에이 항체 부착 이뮤노리포좀
WO2004099780A1 (en) 2003-05-06 2004-11-18 Rigshospitalet Immunoassays for the detection of urokinase receptor forms
CA2546237A1 (en) 2003-11-18 2005-06-02 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
US7541159B2 (en) * 2004-04-14 2009-06-02 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Molecular-specific urokinase antibodies
US8105602B2 (en) 2006-12-08 2012-01-31 Tactic Pharma, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002062295A (ja) * 1989-04-07 2002-02-28 Cancerforskningsfonden Af 1989 (Fonden Til Fremme Af Eksperimentel Cancerforskning) ウロキナーゼ型プラスミノーゲン活性化因子レセプター
WO2005116077A2 (en) * 2004-05-25 2005-12-08 Attenuon, Llc LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY
WO2006090389A2 (en) * 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530510A (ja) * 2013-08-01 2016-09-29 ザ ジェネラル ホスピタル コーポレイション 非グリコシル化ｓｕＰＡＲバイオマーカー及びその使用
JP2023532426A (ja) * 2020-06-15 2023-07-28 モノパー セラピューティクス、インコーポレイテッド 重症ＣＯＶＩＤ－１９疾患の治療のためのウロキナーゼプラスミノーゲン活性化因子受容体（ｕＰＡＲ）の正確な放射線免疫治療標的化

Also Published As

Publication number Publication date
US8105602B2 (en) 2012-01-31
EP2117571A2 (en) 2009-11-18
DK2117571T3 (en) 2017-05-08
CA2671971A1 (en) 2008-06-19
JP2014224134A (ja) 2014-12-04
WO2008073312B1 (en) 2008-12-18
WO2008073312A2 (en) 2008-06-19
WO2008073312A3 (en) 2008-10-30
EP2117571B1 (en) 2017-03-08
PT2117571T (pt) 2017-06-14
ES2636451T3 (es) 2017-10-05
US20080199476A1 (en) 2008-08-21
EP2117571A4 (en) 2010-08-04
CA2671971C (en) 2021-03-30
PL2117571T3 (pl) 2017-08-31
JP6019457B2 (ja) 2016-11-02

Similar Documents

Publication Publication Date Title
JP6019457B2 (ja) ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法
JP4890449B2 (ja) 下流ｕＰＡＲ相互作用を阻害するウロキナーゼ型プラスミノーゲン活性化因子（ｕＰＡ）とそのレセプター（ｕＰＡＲ）との複合体に結合するリガンド：診断または治療における同定および使用
US10584172B2 (en) Humanized monoclonal antibodies and methods of use
CA2881966C (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
JP4824025B2 (ja) トランスフェリンレセプター抗体
CA3063344A1 (en) Novel cd73 antibody, preparation and uses thereof
CN101142236B (zh) Adam-9调节剂
US20250353915A1 (en) Antibodies to galectin-3 and methods of use thereof
KR20130042636A (ko) 항-ανβ6 항체 및 이의 용도
JP2008538289A (ja) 結腸癌および膵臓癌のための、組換え型モノクローナル抗体および対応する抗原
US10640550B2 (en) Monoclonal antibody neutralizing infectivity of all ebola viruses
HK1149483B (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
HK1149483A1 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130423

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140401